Fosbretabulin

Drug Profile

Fosbretabulin

Alternative Names: CA4DP; CA4P; Combretastatin A-4 phosphate - Mateon Therapeutics; Combretastatin A4 prodrug; Combretastatin-A4; Combretastatin-A4 phosphate; CRC 87-09; CRC-98-09; CS-A4; Fosbretabulin disodium; Fosbretabulin tromethamine; NSC-613729; Zybrestat®

Latest Information Update: 19 Mar 2017

Price : $50

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; National Cancer Institute (USA); OXiGENE
  • Class Antineoplastics; Combretastatins; Small molecules; Stilbenes
  • Mechanism of Action Cadherin 5 inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioma; Thyroid cancer; Neuroendocrine tumours
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ovarian cancer; Thyroid cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye disorders; Ovarian cancer

Highest Development Phases

  • Phase II/III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Gastrointestinal cancer; Neuroendocrine tumours
  • Preclinical Leukaemia; Malignant carcinoid syndrome; Pancreatic cancer
  • Suspended Age-related macular degeneration; Thyroid cancer
  • No development reported Choroidal neovascularisation; Colorectal cancer; Head and neck cancer
  • Discontinued Diabetic retinopathy; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 13 Feb 2017 Preclinical data from a combination study released by Mateon Therapeutics
  • 07 Feb 2017 Mateon Therapeutics withdraws a phase I trial prior to enrolment due to lack of funding in Glioma (Second line therapy, Recurrent, Combination therapy, Late stage disease, Metastatic disease) in USA (NCT01052363)
  • 20 Jan 2017 Efficacy and adverse events data from OX4218 and OX4219 phase II trials were presented at the 2016 Gastrointestinal Cancers Symposium (ASCO-GCS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top